EPO mRNA encodes the human erythropoietin (EPO) protein, a hormone that controls erythropoiesis, or red blood cell production. EPO also plays a role in wound healing and the brain’s response to neural injury. Kariko et al. showed that transfection of EPO mRNA in vivo resulted in significant increases of both reticulocyte counts and hematocrits.
Capped with CleanCap® AG cap analog, modified with 5-methoxyuridines
Cap 1 structure with >95% capping efficiency for superior in vivo activity compared to Cap-0 mRNAs
Manufactured with TriLink’s proprietary CleanScript® method to lower dsRNA for improved performance
Ready to use in downstream mRNA applications and formulations
Grade: RUO
This mRNA is capped using CleanCap® Reagent AG, TriLink's co-transciptional capping technology, which results in the naturally occurring Cap-1 structure with >95% capping efficiency. It is manufactured using TriLink’s CleanScript® method, polyadenylated, modified with 5-methoxyuridine, and optimised for mammalian systems. It mimics a fully processed mature mRNA.
CleanCap Reagent AG produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA).
5-methoxyuridine (5moU) is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.
CleanScript method is TriLink’s proprietary in vitro transcription process that is optimised to minimise dsRNA formation and increase mRNA activity in vivo.